Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03523091 · ClinicalTrials.gov registry record · Phase 4
OnabotulinumtoxinA Bladder Injection Study
A Phase 4 study, sponsored by Corewell Health East.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT03523091: Clinical Trial Phase 4 study, sponsored by Corewell Health East.
NCT03523091 is a Phase 4 study that was terminated before completion, run by Corewell Health East. The registered enrollment target is 6 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03523091, a Phase 4 study, was terminated before completion, sponsored by Corewell Health East.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
Patients with overactive bladder (OAB) will be randomly assigned (like a flip of a coin) to receive 100 units of onabotulinumtoxinA injected into the bladder at either 3 sites or 10 sites. Patient satisfaction and the effectiveness of the medication will be evaluated.
Primary Outcome
Participants will be asked to complete a 3-day voiding diary. On the diary participants will record the number of occurrences of voids over a 24 hour period for 3 consecutive days. Number of voids at 3 months are recorded.
Interventions
- DRUG OnabotulinumtoxinA 100Unit Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-08-08 |
| Est. Completion | 2020-09-01 |
| Phase | Phase 4 |
Why NCT03523091 stopped before completion
NCT03523091 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which OnabotulinumtoxinA 100Unit Injection is the first listed.
NCT03523091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03523091 about?
NCT03523091 is a clinical study titled "OnabotulinumtoxinA Bladder Injection Study". Patients with overactive bladder (OAB) will be randomly assigned (like a flip of a coin) to receive 100 units of onabotulinumtoxinA injected into the bladder at either 3 sites or 10 sites. Patient satisfaction and the effectiveness of the medication will be evaluated.
What is the current status of trial NCT03523091?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2018-08-08. Estimated completion is 2020-09-01.
What interventions are being tested in trial NCT03523091?
The interventions under investigation include: OnabotulinumtoxinA 100Unit Injection (DRUG).
Who is sponsoring clinical trial NCT03523091?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03523091's enrollment target sits among peer trials
6 1983rd of 2000 higher than 12 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI